| Dr Mary Beth Ostrom, MD | |
|
2280 E 25th St, Idaho Falls, ID 83404-7542 | |
| (208) 227-2100 | |
| Not Available |
| Full Name | Dr Mary Beth Ostrom |
|---|---|
| Gender | Female |
| Speciality | Psychiatry |
| Experience | 40 Years |
| Location | 2280 E 25th St, Idaho Falls, Idaho |
| Accepts Medicare Assignments | Yes. She accepts the Medicare-approved amount; you will not be billed for any more than the Medicare deductible and coinsurance. |
| Identifier | Type | State | Issuer |
|---|---|---|---|
| 1972668531 | NPI | - | NPPES |
| Taxonomy | Type | License (State) | Status |
|---|---|---|---|
| 2084P0800X | Psychiatry & Neurology - Psychiatry | M5589 (Idaho) | Primary |
| Facility Name | Location | Facility Type |
|---|---|---|
| Eastern Idaho Regional Medical Center | Idaho falls, ID | Hospital |
| Group Practice Name | Group PECOS PAC ID | No. of Members |
|---|---|---|
| Idaho Behavioral Health Services Llc | 7315184272 | 8 |
News Archive
Perrigo Company today announced that it has signed a definitive agreement to acquire substantially all of the assets of Paddock Laboratories, Inc., a privately-held, Minneapolis-based manufacturer and marketer of generic pharmaceutical products for approximately $540 million in cash. Perrigo expects to receive a significant tax benefit as a result of the acquisition of Paddock's assets. The net present value of this tax benefit is estimated to be $95 million.
A marker commonly used to determine if a patient is having a heart attack can also be used to identify stable patients at high risk for deadly cardiac events, according to a new study led by investigators at Brigham and Women's Hospital.
Now, for the first time, UCLA researchers have described cost across an entire care process for low-risk prostate cancer - from the time a patient checks in for his first appointment to his post-treatment follow-up testing - using time-driven activity-based costing. And they found a wide variation in costs for the various available treatments that remained consistent over a 12-year period, indicating a better method to monitor costs could save valuable healthcare dollars, said study first author Dr. Aaron Laviana, a fifth year urology resident.
Researchers have made rapid advances in understanding how to manipulate the immune system safely to destroy cancer cells. Adoptive transfer of haploidentical natural killer cells has shown promise as a treatment option to target and kill cancer cells in a less toxic way than conventional therapies. Now for the first time, scientists will combine NK cell therapy with an immunocytokine to target children with relapsed/refractory disease including those with bulky tumors.
› Verified 1 days ago
| Entity Name | Idaho Behavioral Health Services Llc |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1831435163 PECOS PAC ID: 7315184272 Enrollment ID: O20130513000516 |
News Archive
Perrigo Company today announced that it has signed a definitive agreement to acquire substantially all of the assets of Paddock Laboratories, Inc., a privately-held, Minneapolis-based manufacturer and marketer of generic pharmaceutical products for approximately $540 million in cash. Perrigo expects to receive a significant tax benefit as a result of the acquisition of Paddock's assets. The net present value of this tax benefit is estimated to be $95 million.
A marker commonly used to determine if a patient is having a heart attack can also be used to identify stable patients at high risk for deadly cardiac events, according to a new study led by investigators at Brigham and Women's Hospital.
Now, for the first time, UCLA researchers have described cost across an entire care process for low-risk prostate cancer - from the time a patient checks in for his first appointment to his post-treatment follow-up testing - using time-driven activity-based costing. And they found a wide variation in costs for the various available treatments that remained consistent over a 12-year period, indicating a better method to monitor costs could save valuable healthcare dollars, said study first author Dr. Aaron Laviana, a fifth year urology resident.
Researchers have made rapid advances in understanding how to manipulate the immune system safely to destroy cancer cells. Adoptive transfer of haploidentical natural killer cells has shown promise as a treatment option to target and kill cancer cells in a less toxic way than conventional therapies. Now for the first time, scientists will combine NK cell therapy with an immunocytokine to target children with relapsed/refractory disease including those with bulky tumors.
› Verified 1 days ago
| Mailing Address | Practice Location Address |
|---|---|
| Dr Mary Beth Ostrom, MD Po Box 742358, Atlanta, GA 30374-2358 Ph: () - | Dr Mary Beth Ostrom, MD 2280 E 25th St, Idaho Falls, ID 83404-7542 Ph: (208) 227-2100 |
News Archive
Perrigo Company today announced that it has signed a definitive agreement to acquire substantially all of the assets of Paddock Laboratories, Inc., a privately-held, Minneapolis-based manufacturer and marketer of generic pharmaceutical products for approximately $540 million in cash. Perrigo expects to receive a significant tax benefit as a result of the acquisition of Paddock's assets. The net present value of this tax benefit is estimated to be $95 million.
A marker commonly used to determine if a patient is having a heart attack can also be used to identify stable patients at high risk for deadly cardiac events, according to a new study led by investigators at Brigham and Women's Hospital.
Now, for the first time, UCLA researchers have described cost across an entire care process for low-risk prostate cancer - from the time a patient checks in for his first appointment to his post-treatment follow-up testing - using time-driven activity-based costing. And they found a wide variation in costs for the various available treatments that remained consistent over a 12-year period, indicating a better method to monitor costs could save valuable healthcare dollars, said study first author Dr. Aaron Laviana, a fifth year urology resident.
Researchers have made rapid advances in understanding how to manipulate the immune system safely to destroy cancer cells. Adoptive transfer of haploidentical natural killer cells has shown promise as a treatment option to target and kill cancer cells in a less toxic way than conventional therapies. Now for the first time, scientists will combine NK cell therapy with an immunocytokine to target children with relapsed/refractory disease including those with bulky tumors.
› Verified 1 days ago
Bradford L Talcott, M.D. Psychiatry & Neurology Medicare: Accepting Medicare Assignments Practice Location: 2353 Coronado St, Idaho Falls, ID 83404 Phone: 208-552-4823 | |
Dr. Ronald M. Zohner, M.D. Psychiatry & Neurology Medicare: May Accept Medicare Assignments Practice Location: 1842 1st St, Idaho Falls, ID 83401 Phone: 208-552-5707 Fax: 208-552-5709 | |
Adam Nielsen Burch, DO Psychiatry & Neurology Medicare: Accepting Medicare Assignments Practice Location: 2280 E 25th St, Idaho Falls, ID 83404 Phone: 208-227-2100 Fax: 208-227-2362 | |
Dr. Debra S Gorin, MD PC Psychiatry & Neurology Medicare: Not Enrolled in Medicare Practice Location: 1361 Cambridge Dr, Idaho Falls, ID 83401 Phone: 208-535-8549 Fax: 208-528-8109 | |
Ms. Susan Lynn Bunnell, MD Psychiatry & Neurology Medicare: Not Enrolled in Medicare Practice Location: 2280 E 25th Street, Idaho Falls, ID 83404 Phone: 208-227-2295 Fax: 208-227-2364 | |
Daniel Lilligren, MD Psychiatry & Neurology Medicare: Accepting Medicare Assignments Practice Location: 2280 E 25th St, Idaho Falls, ID 83404 Phone: 208-227-2100 Fax: 208-227-2362 | |
Dr. Jesse Hinckley, MD, PHD Psychiatry & Neurology Medicare: Accepting Medicare Assignments Practice Location: 2280 E 25th St, Idaho Falls, ID 83404 Phone: 208-227-2100 |